Private Equity Physician Deals Fall by Half in 2026 as States Tighten Oversight
Turn adjusted EBITDA and a few practice details into a directional enterprise-value range with our Healthcare Practice Valuation Calculator. Educational and directional, and no email required.
Private equity acquisitions of physician practice management (PPM) companies are on track to fall by roughly half in 2026, according to new PitchBook data reported by STAT. Deal volume has collapsed from a 2021 peak of 851 transactions to just 105 in the first half of 2026. STAT attributes much of the slowdown to a wave of new state laws—now on the books in more than a dozen states—that expand government oversight of private equity healthcare deals and corporate practice of medicine (CPOM) arrangements. Reed Smith healthcare partner Paul Pitts called the decline significant, signaling a more cautious, regulation-shaped dealmaking environment for PPM platforms and their sponsors.
For PE sponsors and multi-site operators, the deal window is narrowing: tighter state CPOM rules and slower PPM dealmaking mean valuations, exit timing, and platform-expansion plans now hinge on regulatory exposure as much as EBITDA. Diligence on state-by-state compliance is becoming a gating factor, not an afterthought.
While we aim to share useful and relevant resources, we do not guarantee the accuracy of content on this site or any external links. Views and opinions expressed in referenced content do not necessarily reflect those of Healthcare Growth Strategies.
How much have private equity physician practice deals dropped in 2026?
Private equity deals for physician practice management (PPM) companies are on pace to fall by about half in 2026 versus 2025. PitchBook data show transactions declining from a 2021 high of 851 to just 105 in the first half of 2026.
Why are private equity healthcare deals slowing down?
A major driver is regulation. More than a dozen states have enacted laws expanding oversight of private equity healthcare transactions and corporate practice of medicine (CPOM) structures, adding compliance friction and deal risk. Shifting macroeconomic conditions and heightened scrutiny of practice financials are compounding the slowdown.
What does the PPM slowdown mean for practice owners and sponsors?
Sellers face fewer and more selective buyers, while sponsors must weigh state-level regulatory exposure alongside financial performance. Deal structuring, valuations, and exit timing increasingly depend on how a platform navigates corporate practice of medicine rules in each state it operates.